Apply these seven points to any telehealth GLP-1 provider before paying for an intake. The first three filter out providers that shouldn't exist; the next four separate providers that look similar on the surface.
1. Clinician credentials and oversight
Ask whether a licensed clinician is actually reviewing your intake, not just a software workflow rubber-stamping a checkbox form. Strong providers name their medical leadership publicly, list the states where their clinicians are licensed, and explain how follow-up consultations are handled. If you can't find a named clinician anywhere on the provider's site, treat that as a signal to keep looking.
2. Eligibility transparency
Look for clear, up-front statements about who qualifies, including BMI thresholds, age ranges, contraindications, and conditions that automatically rule someone out. Vague eligibility language like 'our clinicians will assess if treatment is right for you' is a flag. You should be able to know if you'll likely be denied before paying for an intake.
3. Pricing clarity beyond the first month
The published monthly price should include medication, clinician review, and shipping. If labs, refills, dose changes, or follow-up consultations cost extra, the real monthly cost is higher than advertised. The cheapest providers are sometimes the cheapest because they unbundle aggressively. Ask explicitly: what does the month-two-onwards price actually cover?
4. Medication route and pharmacy sourcing
Compounded semaglutide, brand-name Wegovy, or both? Compounded has historically been lower-cost, but its availability is now limited and legally uncertain. The FDA declared the semaglutide (Feb 2025) and tirzepatide (Oct 2024) shortages resolved, which ended routine compounding of copies, and an April 2026 FDA proposal would restrict it further (final determination pending). Where a provider still offers a compounded option, ask which pharmacy it uses, whether it is 503A or 503B registered (the FDA categories for compounding), and what quality controls and legal basis are in place. For brand-name Wegovy, confirm the medication is dispensed through a licensed retail or specialty pharmacy.
5. Refill cadence and dose progression
How are refills triggered? Automatically each month, or after a clinician check-in? How is dose increase decided? By you, by the clinician, or by a default schedule? A provider that ships month after month with no contact is treating GLP-1 as a subscription rather than supervised medical care. Strong providers build in regular touchpoints, especially in months one through four when dose escalation typically happens.
6. Side-effect handling and clinician access
What happens when you experience nausea, fatigue, constipation, or anything more serious? Is there a clinician messaging channel? What's the response time? Can you switch medications or pause without losing your money? Side effects are the rule, not the exception, with GLP-1 treatment. A provider with weak or slow side-effect channels will leave you stranded mid-dose.
7. Cancellation, refund, and continuity
Can you stop the program if it's not working? Are unused medications refundable or transferrable? Are you locked into an annual contract? What happens to your medical record and dose history if you switch providers? GLP-1 programs are not one-month commitments, so find out the exit terms before the entry terms.
Regulatory note: After the FDA declared the semaglutide shortage resolved in February 2025, pharmacies could no longer routinely compound copies of that licensed product. On May 1, 2026 the FDA published a notice proposing not to include semaglutide, tirzepatide or liraglutide on the 503B Bulks List; a final determination is still pending. The availability and pricing described here may not reflect what a provider can currently supply, so confirm the current offering and cost directly with any provider before relying on it.
Last reviewed: July 2026Source: FDA: Declaratory Order: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy) · United States · Decision February 21, 2025
Source: FDA: Federal Register notice — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B · United States · Published May 1, 2026